Boston Scientific Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Boston Scientific wird ein jährliches Gewinn- und Umsatzwachstum von 23.2% bzw. 10.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 22.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 17.3% betragen.
Wichtige Informationen
23.2%
Wachstumsrate der Gewinne
22.8%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 17.1% |
| Wachstumsrate der Einnahmen | 10.2% |
| Zukünftige Eigenkapitalrendite | 17.3% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 18 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Why The Fundamentals Make Me Bullish On Boston Scientific
Oct 31Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio
Oct 23Is Boston Scientific (NYSE:BSX) A Risky Investment?
Oct 10
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement
Sep 24Boston Scientific: Forward Returns Are Likely To Be Disappointing For Investors
Sep 20Boston Scientific Corporation's (NYSE:BSX) P/E Still Appears To Be Reasonable
Sep 09A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 23The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business
Aug 08Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
Jul 17Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching
Jul 05Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?
Jun 21Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Jun 08Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 20,510 | 3,451 | 3,892 | 4,405 | 28 |
| 12/31/2025 | 18,607 | 2,843 | 2,898 | 3,777 | 31 |
| 12/31/2024 | 16,577 | 1,977 | 2,727 | 3,797 | 30 |
| 9/30/2024 | 15,911 | 1,793 | 2,179 | 2,936 | N/A |
| 6/30/2024 | 15,229 | 1,828 | 1,866 | 2,632 | N/A |
| 3/31/2024 | 14,707 | 1,765 | 1,726 | 2,477 | N/A |
| 12/31/2023 | 14,240 | 1,570 | 1,822 | 2,503 | N/A |
| 9/30/2023 | 13,757 | 1,191 | 1,736 | 2,353 | N/A |
| 6/30/2023 | 13,400 | 861 | 1,559 | 2,125 | N/A |
| 3/31/2023 | 13,045 | 846 | 1,256 | 1,774 | N/A |
| 12/31/2022 | 12,682 | 642 | 1,008 | 1,526 | N/A |
| 9/30/2022 | 12,567 | 596 | 629 | 1,197 | N/A |
| 6/30/2022 | 12,329 | 828 | 668 | 1,192 | N/A |
| 3/31/2022 | 12,162 | 754 | 1,007 | 1,528 | N/A |
| 12/31/2021 | 11,888 | 985 | 1,398 | 1,870 | N/A |
| 9/30/2021 | 11,470 | 1,101 | 1,701 | 2,065 | N/A |
| 6/30/2021 | 11,196 | 526 | 1,939 | 2,243 | N/A |
| 3/31/2021 | 10,122 | 201 | 1,604 | 1,869 | N/A |
| 12/31/2020 | 9,913 | -115 | 1,219 | 1,508 | N/A |
| 9/30/2020 | 10,108 | 3,685 | 1,242 | 1,527 | N/A |
| 6/30/2020 | 10,157 | 3,980 | 1,008 | 1,386 | N/A |
| 3/31/2020 | 10,785 | 4,287 | 986 | 1,409 | N/A |
| 12/31/2019 | 10,735 | 4,700 | 1,427 | 1,836 | N/A |
| 9/30/2019 | 10,392 | 1,090 | 782 | 1,163 | N/A |
| 6/30/2019 | 10,077 | 1,396 | 826 | 1,162 | N/A |
| 3/31/2019 | 9,937 | 1,797 | 148 | 467 | N/A |
| 12/31/2018 | 9,823 | 1,671 | -6 | 310 | N/A |
| 9/30/2018 | 9,670 | 670 | 686 | 975 | N/A |
| 6/30/2018 | 9,500 | 521 | N/A | 926 | N/A |
| 3/31/2018 | 9,267 | 112 | N/A | 1,626 | N/A |
| 12/31/2017 | 9,048 | 104 | N/A | 1,426 | N/A |
| 9/30/2017 | 8,831 | 843 | N/A | 1,418 | N/A |
| 6/30/2017 | 8,714 | 788 | N/A | 935 | N/A |
| 3/31/2017 | 8,582 | 435 | N/A | 1,059 | N/A |
| 12/31/2016 | 8,386 | 347 | N/A | 1,182 | N/A |
| 9/30/2016 | 8,095 | 81 | N/A | 835 | N/A |
| 6/30/2016 | 7,878 | -345 | N/A | 1,274 | N/A |
| 3/31/2016 | 7,595 | -36 | N/A | 913 | N/A |
| 12/31/2015 | 7,477 | -239 | N/A | 691 | N/A |
| 9/30/2015 | 7,314 | -396 | N/A | 711 | N/A |
| 6/30/2015 | 7,272 | -155 | N/A | 649 | N/A |
| 3/31/2015 | 7,302 | -253 | N/A | 874 | N/A |
| 12/31/2014 | 7,308 | -119 | N/A | 1,269 | N/A |
| 9/30/2014 | 7,258 | 288 | N/A | 1,104 | N/A |
| 6/30/2014 | 7,147 | 240 | N/A | 1,009 | N/A |
| 3/31/2014 | 7,083 | 366 | N/A | 1,121 | N/A |
| 12/31/2013 | 7,070 | -121 | N/A | 1,110 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: BSXDas prognostizierte Gewinnwachstum (23.2% pro Jahr) liegt über der Sparquote (2.6%).
Ertrag vs. Markt: BSXDie Erträge des Unternehmens (23.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.3% pro Jahr).
Hohe Wachstumserträge: BSXEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: BSXDie Einnahmen des Unternehmens (10.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).
Hohe Wachstumseinnahmen: BSXDie Einnahmen des Unternehmens (10.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: BSXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (17.3%).